Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02031419
Title Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | ITA | FRA | CAN

Facility Status City State Zip Country Details
Stanford Cancer Center Stanford California 94305 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
Local Institution - 005 Tampa Florida 33612 United States Details
Northwestern University Chicago Illinois 60611 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Local Institution - 001 Nashville Tennessee 37203 United States Details
MD Anderson Cancer Center Houston Texas 77030-400 United States Details
Local Institution - 007 Madison Wisconsin 53792 United States Details
Local Institution - 402 Edmonton Alberta T6G 1Z2 Canada Details
Local Institution - 400 Toronto Ontario M5G 2M9 Canada Details
Local Institution - 102 Bordeaux 33076 France Details
Local Institution - 101 Lyon 69373 France Details
Local Institution - 100 Villejuif CEDEX 94805 France Details
Local Institution - 202 Milano 20133 Italy Details
Local Institution - 200 Rozzano (MI) 20089 Italy Details
Local Institution - 201 Turin 10126 Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field